Ru Back Packer

Quotes delayed 20 minutes



If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Ru Back Packer Staff, updated Thursday, February 1, 7:41 AM

Slide #150. CTI BioPharma Corp. Preferred Stock Offering

Company: CTI BioPharma Corp. (NASDAQ:CTIC)
Date announced: 10/26/2015
Shares Offered: 50,000
Date of Pricing: 10/27/2015
Price Per Share: $1,000
Preferred Stock Offering Details: CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-1 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-1 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic conversion of such shares in certain circumstances. -updated 10/27- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 50,000 shares of its Series N-1 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-1 Preferred Stock (the "Offering"). Each share of Series N-1 Preferred Stock is convertible at the option of the holder, at any time, into 800 shares of common stock at a conversion price of $1.25 per share of common stock, for a total of 40,000,000 shares of common stock. The shares of Series N-1 Preferred Stock will automatically convert into shares of common stock in certain circumstances.

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of therapies covering a range of blood-related cancers. Co. is primarily focused on treatments that target blood-related cancers where there is an unmet medical need. In particular, Co. is primarily focused on commercializing PIXUVRI® (pixantrone) in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, and evaluating pacritinib for the treatment of adult patients with myelofibrosis.
Open the CTIC Page at Ru Back Packer »

Name: CTI BioPharma Corp
Website: celltherapeutics.com
Sector: Biotechnology
Number of ETFs Holding CTIC: 4 (see which ones)
Total Market Value Held by ETFs: $280,061
Total Market Capitalization: $133,000,000
% of Market Cap. Held by ETFs: 0.21%

Open the CTIC Page at Ru Back Packer (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference

The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500

Preferred Stock Offerings - Slide 150 of 414 | rubackpacker.com | Copyright © 2011 - 2018, All Rights Reserved